The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
In this study, We investigated the efficacy and safty of camrelizumab combined with S-1 maintenance after first-line induction chemotherapy for GC. Patients without progressive disease after 4-6 weeks of first-line chemotherapy with SOX will be treated with camrelizumab combined with S-1.
Epistemonikos ID: a69696b5327cdf1daac9faf49246cd0bdfbe4b32
First added on: May 09, 2024